Alkem Laboratories rises on launching `Pertuza` injection
Alkem Laboratories is currently trading at Rs. 5558.00, up by 62.00 points or 1.13% from its previous closing of Rs. 5496.00 on the BSE.
The scrip opened at Rs. 5554.95 and has touched a high and low of Rs. 5558.00 and Rs. 5504.00 respectively. So far 1729 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 6369.00 on 09-Oct-2024 and a 52 week low of Rs. 4498.90 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 5571.50 and Rs. 5453.45 respectively. The current market cap of the company is Rs. 66239.61 crore.
The promoters holding in the company stood at 53.04%, while Institutions and Non-Institutions held 30.91% and 16.05% respectively.
Alkem Laboratories (Alkem) has launched Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer. Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab. In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator.
Accessibility of pertuzumab in India has remained a significant challenge and only limited HER2-postive breast cancer patients are able to use it in their treatment due to cost barriers. By bringing an affordable pertuzumab biosimilar, backed by research, regulatory-compliant manufacturing, and strong oncology distribution network, Alkem strives to ensure scientific credibility and improved accessibility.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
